Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: Pharmacokinetics, safety, and efficacy
Autore:
Burger, DM; Hugen, PWH; Aarnoutse, RE; Dieleman, JP; Prins, JM; van der Poll, T; ten Veen, JH; Mulder, JW; Meenhorst, PL; Blok, WL; van der Meer, JTM; Reiss, P; Lange, JMA;
Indirizzi:
Univ Nijmegen, Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands Univ Nijmegen Nijmegen Netherlands pt Clin Pharm, Nijmegen, Netherlands Univ Rotterdam Hosp, Rotterdam, Netherlands Univ Rotterdam Hosp Rotterdam Netherlands Hosp, Rotterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands Univ Amsterdam Amsterdam Netherlands NL-1105 AZ Z Amsterdam, Netherlands OLVG Prinsengracht Hosp, Dept Internal Med, Amsterdam, Netherlands OLVG Prinsengracht Hosp Amsterdam Netherlands d, Amsterdam, Netherlands Slotervaart Hosp, Dept Internal Med, Amsterdam, Netherlands Slotervaart Hosp Amsterdam Netherlands rnal Med, Amsterdam, Netherlands Natl AIDS Therapy Evaluat Ctr, Amsterdam, Netherlands Natl AIDS Therapy Evaluat Ctr Amsterdam Netherlands terdam, Netherlands Walcheren Hosp, Dept Internal Med, Vlissingen, Netherlands Walcheren HospVlissingen Netherlands rnal Med, Vlissingen, Netherlands
Titolo Testata:
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
fascicolo: 3, volume: 26, anno: 2001,
pagine: 218 - 224
SICI:
1525-4135(20010301)26:3<218:ARCSOP>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
PERFORMANCE LIQUID-CHROMATOGRAPHY; HIV-PROTEASE INHIBITOR; PLASMA-CONCENTRATIONS; THERAPY; SAQUINAVIR; FAILURE;
Keywords:
indinavir; ritonavir; pharmacokinetics; efficacy; safety;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Burger, DM Univ Med Ctr 533KF, Dept Clin Pharm, POB 9101, NL-6500 HB Nijmegen, Netherlands Univ Med Ctr 533KF POB 9101 Nijmegen Netherlands NL-6500 HB ds
Citazione:
D.M. Burger et al., "A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: Pharmacokinetics, safety, and efficacy", J ACQ IMM D, 26(3), 2001, pp. 218-224

Abstract

Objective: To describe the pharmacokinetics. safety, and efficacy of twice-daily indinavir + ritonavir regimensDesign: A cohort-based survey of HIV-infected patients who either used indinavir 800 mg + ritonavir 100 mg twice daily or indinavir 400 mg + ritonavir 300 mg twice daily. Methods: Data were extracted from a database of samples sent to our laboratory for measurement of indinavir + ritonavir plasma concentrations. Patient characteristics, safety, and efficacy measurements were collected by retrospective chart review. Results: 100 Patients using 800-mg indinavir + 100-mg ritonavir twice daily and 32 patients using 400-mg indinavir + 400-mg ritonavir twice daily were eligible. Median peak and trough concentrations of indinavir were 6.8 and0.77 mg/L in the 800/100 group and 2.6 and 0.45 mg/L in the 400/400 group. The most frequently found side effects were nausea and vomiting, which occurred in 22.1% and 34.9% of the patients in the 800/100 and the 400/400 groups, respectively. Viral load data were analyzed for patients who switched from 800-mg indinavir three times daily to one of the indinavir + ritonavirtwice daily regimens. At the time of switch 63% (800/100 group) and 60% (400/400 group) had an undetectable viral load and this increased to 77% and 70%, respectively, during follow-up. Patients who switched to the 400/400 group discontinued treatment more frequently than patients who switched to the 800/100 group (70% vs. 26%, p = .008). Conclusions: Indinavir + ritonavir regimens show improved pharmacokinetic properties, allowing twice-daily dosing with feud. Clinical data suggest that safety and efficacy is at least as good as with indinavir three-times-daily regimens without ritonavir. Prospective, comparative trials are needed to properly assess the role in HIV therapy of these twice-daily indinavir ritonavir regimens.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 16:04:21